GlassScriptPhysician profile
Gillian C Redlich
NPI 1659444701
$438.79
in general payments reported to CMS, 2019-2025
13 companies · $269 in 2025
The $269 reported for 2025 was more than what 82% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.81 · 2024: $113 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $56.81 | 2020 | |
| Genentech USA, INC. | $56.27 | 2024-2025 | Polivy, Tecentriq, Phesgo |
| Merck Sharp & Dohme LLC | $53.46 | 2024-2025 | Keytruda, Lenvima |
| Astellas Pharma US INC | $49.66 | 2025 | Vyloy, Xtandi |
| Pharmacosmos Therapeutics INC. | $33.34 | 2024 | Monoferric |
| Janssen Biotech, INC. | $32.87 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Stemline Therapeutics INC. | $31.48 | 2024-2025 | Orserdu |
| Pharmaessentia USA Corporation | $24.17 | 2025 | Besremi |
| Beone Medicines USA, INC. | $22.75 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $21.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.92 | 2025 | Lynparza |
| Aveo Pharmaceuticals, INC. | $19.39 | 2025 | |
| Beigene USA, INC. | $16.11 | 2024 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gillian Redlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.